Redeye revisits its view of Cereno Scientific before the imminent TO2 exercise and coming phase II data from the company’s trial with lead candidate CS1 in PAH in Q1 2023E. We judge that positive phase II data could propel the company to the next level, paving the way to a potentially pivotal phase II/III trial in H1 2024E.

Länk till analysen